Profusa Adopts NVIDIA-Powered Technology to Build AI-Driven Insight Portal for Continuous Biomarker Monitoring
Company expects early 2026 rollout in EEA; physician portal combines Lumee oxygen monitoring with NVIDIA NeMo to deliver AI-driven clinical workflows
Profusa, a commercial stage digital health company pioneering a next-generation technology platform enabling the continuous monitoring of an individual’s biochemistry, announces the adoption of NVIDIA technology to power an AI-driven insight portal for continuous biochemistry monitoring.
“We believe that real-time biochemistry data across a large population is a data-set that is currently missing to enable the fulfillment of the promise of AI-enabled improvement in healthcare. Profusa is uniquely positioned to provide this proprietary data set, linking therapeutic decisions with real-time biochemistry changes, to generate valuable insights that are lacking today.” Ben Hwang, Ph.D., Profusa’s Chairman and CEO commented, “By combining our Lumee platform with the industry leading NVIDIA NeMo hardware and software stack, we plan to build an AI-fueled, scalable technology backbone for better personalized sensor data accuracy and real-time sensor data connections with electronic medical records (EMR), facilitating treatment and outcome predictions, in addition to establishing a robust data base for clinical literature for disease management.”
Also Read: AiThority Interview with Tim Morrs, CEO at SpeakUp
Expected capabilities and feature sets from the physician portal include:
- Agentic clinical workflows: A large language model (LLM) powered assistant for clinicians that integrates with EMRs, wearables, and home devices to assist with notes, orders, care plans, remote physiologic monitoring (RPM)/remote therapeutic monitoring (RTM), triage, and escalations
- Evaluation and monitoring: Built-in experimentation and metrics to assess assistant quality, drift, and safety over time
- Guardrails by design: Policy-aware orchestration to enforce clinical scope, data privacy, and safe responses across patient and provider experiences
- Model training options: From parameter-efficient tuning to post-training refinement of Profusa’s AI signal processing and clinical reasoning components
- Time-aligned health data graph: A longitudinal view that fuses Profusa biomarkers with EMR data (problems, meds, labs, vitals, imaging, notes), claims/pharmacy, wearables/IoT, genomics, and social determinants to power predictions and coaching
“We believe physicians need trustworthy, always-on insights, not more dashboards. Our intention is for this cutting-edge portal technology to answer this need by translating raw optical signals into reliable biometrics, providing actionable clinical context.” concluded Dr. Hwang.
The portal will be used in combination with Profusa’s Lumee oxygen optical hydrogel sensors and reader system, extending Profusa’s AI-enabled signal processing and care team tools from clinician offices to remote patient monitoring settings. Profusa expects an early 2026 rollout of the portal in the European Economic Area (EEA) —consisting of the EU, Lichtenstein, Norway, and Iceland — which accepts the CE Mark.
[To share your insights with us as part of editorial or sponsored content, please write to psen@itechseries.com]
Comments are closed.